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Abstract The alveolar cleft in patients with clefts of lip,
alveolus and palate (CLAP) is usually reconstructed with an
autologousbonegraft.Harvestingofautologousbonegraftsis
associated with more or less donor site morbidity. Donor site
morbidity could be eliminated if bone is fabricated by growth
factor-aided tissue engineering. The objective of this review
was to provide an oversight on the current state of the art in
growth factor-aided tissue engineering with regard to recon-
struction of the alveolar cleft in CLAP. Medline, Embase and
Central databases were searched for articles on bone morpho-
genetic protein 2 (BMP-2), bone morphogenetic protein 7,
transforming growth factor beta, platelet-derived growth
factor, insulin-like growth factor, fibroblast growth factor,
vascularendothelial growthfactorandplatelet-rich plasmafor
the reconstruction of the alveolar cleft in CLAP. Two-hundred
ninety-one unique search results were found. Three articles
met our selection criteria. These three selected articles
compared BMP-2-aided bone tissue engineering with iliac
crest bone grafting by clinical and radiographic examinations.
Bonequantityappearedcomparablebetweenthetwomethods
inpatientstreatedduringthestageofmixeddentition,whereas
bone quantity appeared superior in the BMP-2 group in
skeletally mature patients. Favourable results with BMP-2-
aided bone tissue engineering have been reported for the
reconstruction of the alveolar cleft in CLAP. More studies are
necessary to assess the quality of bone. Advantages are
shortening of the operation time, absence of donor site
morbidity, shorter hospital stay and reduction of overall cost.
Keywords Growth factor.Cleftsoflip, alveolusand palate.
Bone morphogenetic protein 2.Bone graft
Background
The incidence of clefts of lip, alveolus and palate (CLAP)
varies between races [1]. Mongolians are affected, with
incidence of 0.55–2.50 per 1,000 births; Caucasians, 0.69–
2.35 per 1,000 births and Negroids, 0.18–0.82 per 1,000
births [1]. Males are more often affected than females [2].
A cleft of the alveolus is present in more than 50% of the
cases with CLAP [3].
CLAP is caused by incomplete fusion of the facial
prominences during the fourth to tenth week of gestation.
Failure of the maxillary prominences to fuse with the
intermaxillary prominence results in a cleft of the primary
palate. Failure of fusion of the two palatine shelves of the
maxillary prominences produces a cleft of the secondary
palate. Clefts of the primary palate result in a cleft lip or in
a cleft lip and alveolus, clefts of the secondary palate result
in a cleft of the palate, and clefts of the primary plus
secondary palate result in a cleft of the lip, alveolus and
palate or a cleft of the lip and palate [4].
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provide continuity and stabilization of the maxillary arch, to
close the oronasal fistula, to permit tooth eruption, to
provide support of the alar base and to improve nasal
symmetry [5]. The alveolar cleft is usually reconstructed in
the stage of mixed dentition between 7 and 11 years.
Autologous bone graft has been the gold standard of bone
replacement for many years because it provides osteogenic
cells as well as essential osteoinductive factors needed for
bone healing and regeneration. It can be taken from the
patient’s iliac crest, mandibular symphysis, rib, tibia and
calvarium, with each donor site having its specific
advantages and disadvantages [6]. Regardless of the site
of bone graft harvest, however, there is always more or less
donor site morbidity such as postoperative pain, altered
sensation, donor site infection and scarring [6, 7]. Growth
factor-aided tissue engineering for the reconstruction of the
alveolar cleft may eliminate a second surgical site for the
harvest of autologous bone and would thus eliminate donor
site morbidity [8].
Tissue engineering
The three vital components necessary for the engineering of
bone are bone-forming cells, osteoinductive growth hormone
and an osteoconductive scaffold. The osteoconductive scaf-
foldprovidesimmediatemechanicalsupport,mimicsthebony
extracellular matrix and guides the formation of bone in the
desiredshapeandplace.Thescaffoldshouldbebiocompatible
andbiodegradable.Therateofdegradationisideallyinversely
proportional to the rate of bone formation. Several synthetic
and organic polymers and also ceramics have been proposed
as materials to produce scaffolds [9, 10].
The scaffold may also serve as a carrier for the
osteoinductive growth hormone. The growth hormone is
thus delivered locally and ideally over a sustained period of
time. The main role of the growth hormone is to recruit
mesenchymal stem cells to the area and make them
differentiate into an osteogenic cell lineage [9–11].
Growth factors
Many growth factors are involved in osteogenesis. Bone
morphogenetic proteins (BMP-2 and BMP-7), transforming
growth factor beta (TGF-β), insulin-like growth factors I
and II (IGF I and II), platelet-derived growth factor
(PDGF), fibroblast growth factors (FGF) and vascular
endothelial growth factor (VEGF) have been proposed for
use in bone tissue engineering [9, 12, 13].
Bone morphogenetic proteins (BMPs) are a group of
proteins known to play a role in osteogenesis and chondro-
genesis. BMPs are also involved in embryonic development
and fracture healing. Especially BMP-2 and BMP-7 are
known for their osteoinductive qualities [9, 11–13]. TGF-β
plays a role in osteogenesis, its actions are diverse and
TGF-β is thought to influence the activity of BMPs [9, 12,
13]. IGFs I and II are present in fracture healing sites. IGFs
I and II both stimulate type-1 collagen synthesis and
decrease collagenase synthesis [9, 12, 13]. PDGF recruits
mesenchymal stem cells and promotes angiogenesis [9, 13].
FGF plays a role in maintaining the balance between bone-
forming cells and bone-resorbing cells and promotes
angiogenesis [9, 12]. VEGF plays a role in angiogenesis,
promotes vasodilatation and increases microvascular per-
meability [9, 12].
Platelet-rich plasma (PRP) contains a wide diversity of
growth factors, and therefore, PRP is thought to stimulate
bone formation. Growth factors known to be present in
PRP are TGF-β, PDGF, IGF, FGF, VEGF, endothelial cell
growth factor and epidermal growth factor [14].
Clinical application of growth factors
PRP has been applied for reconstruction of the maxillofa-
cial skeleton with contradictory results [14, 15].
Recombinant human PDGF (rhPDGF) has been ap-
proved by the Food and Drug Administration for the repair
of periodontal defects. RhPDGF has been studied in
combination with β-tricalcium phosphate and in combina-
tion with IGF in a gel delivery system for the repair of
periodontal defects [16–18].
Recombinant human BMP-2 (rhBMP-2) in combination
with a collagen sponge carrier made out of type 1 bovine
collagen has been approved by the Food and Drug
Administration and is used for specific clinical situations,
i.e. interbody spinal fusion, open tibial fractures, sinus
augmentation and alveolar ridge augmentation after dental
extraction [19, 20].
Recombinant human BMP-7 (rhBMP-7) is used in non-
union of long bone fractures and spinal fusion and has been
approved by the Food and Drug Administration for these
indications. A study has been performed with rhBMP-7 for
sinus floor elevation [20, 21].
Literature review
Search
An electronic search was conducted on MEDLINE,
EMBASE and CENTRAL databases through PubMed,
Embase and Cochrane. The search strategy was aiming
towards sensitivity rather than precision. The search
298 Clin Oral Invest (2011) 15:297–303command on each database consisted of two factors: the
domain, cleft alveolus, and the determinant, the growth
factor, both to be found in title and/or abstract. Searches
were conducted for BMP-2, BMP-7, TGF-β, PDGF, IGF,
FGF, VEGF and PRP. For each growth factor, synonyms
and spelling variants were taken into account.
Method
The search results were checked for doubles. Then, the
unique search results were checked against our inclusion
and exclusion criteria on basis of title and/or abstract
screening. Articles that met the selection criteria on basis of
title and/or abstract screening were double checked against
the selection criteria by means of full text analysis.
Included were clinical trials and retrospective studies
describing the method of reconstruction of the alveolar cleft
with growth factor-aided bone tissue engineering in CLAP
patients. The exclusion criteria were: use of autologous
bone graft, including bone marrow aspirate; previous
attempt to reconstruct the alveolar cleft; absence of
radiographic quantification of bone in the reconstructed
cleft; language of the full text article other than English.
Search results
The search yielded 41 results for BMP-2, 12 results for
BMP-7, 73 results for TGF-β, 25 results for PDGF, 32
results for IGF, 96 results for FGF, 21 results for VEGF and
21 results for PRP. After checking for doubles, 34 unique
results were left for BMP-2, 10 for BMP-7, 71 for TGF-β,
22 for PDGF, 31 for IGF, 86 for FGF, 19 for VEGF and 18
for PRP.
Title and/or abstract screening
Six studies on BMP-2 and seven studies on PRP met the
inclusion criteria. One of these BMP-2 studies was
excluded because the full text article was only available in
Chinese. Six of the PRP studies were excluded because an
autologous bone graft was used in combination with PRP.
Five BMP-2 studies and one PRP study were admitted for
full text analysis. The results of the title and/or abstract
screening are displayed in Table 1.
Full text analysis
Three articles were excluded on basis of the full text
screening. The article by Chin et al. [22] on BMP-2 was
excluded because besides CLAP, facial clefts were recon-
structed and because of absence of radiographic quantifi-
cation of bone in the reconstructed cleft. The article by
Fallucco et al. [23] on BMP-2 was excluded because of
absence of radiographic quantification of bone in the
reconstructed cleft. The article by Hibi et al. [24] on PRP
was excluded because bone marrow aspirate was used.
Finally, three articles were accepted for the review
(Table 2). These three articles were on the reconstruction
of the alveolar cleft with the use of BMP-2 in the
experimental group and with autologous bone graft in the
control group.
In all three articles, unilateral clefts only were included.
Prior alveolar surgery was an exclusion criterion for
patients in Alonso et al. [25] and Dickinson et al. [26].
No mention of prior alveolar surgery was made by Herford
et al. [27].
In the three studies, the kit of Infuse® Bone Graft
(Medtronic, Sofamor Danek, Memphis, TN) was used. This
kit contains an absorbable sponge consisting of type 1
bovine collagen and is impregnated with rhBMP-2. In the
three studies, reconstruction of the alveolar cleft in the
control group was performed with autologous cancellous
bone of the iliac crest.
Mean alveolar cleft size prior to surgery was 0.975 cm
3 in
the BMP-2 group versus 1.052 cm
3 in the control group in
Alonso et al. [25], 5.6 cm
3 versus 5.1 cm
3 in Dickinson et al.
[26] and 10.55 cm
3 versus 17.86 cm
3 in Herford et al. [27].
In the studies by Alonso et al. [25] and Dickinson et al.
[26], all patients received preoperative orthodontic expan-
sion of the maxillary segments. No mention of preoperative
treatment was made by Herford et al. [27].
Timing of the reconstruction of the alveolar cleft varied
between the three studies; Alonso et al. [25] and Herford et
al. [27] reconstructed the alveolar clefts during the stage of
mixed dentition, whereas Dickinson et al. [26] recon-
structed the clefts in skeletally mature patients.
Computed tomography (CT) was used to evaluate bone
formation and to measure the quantity of bone formation:
Alonso et al. [25] performed a CT at 6 and at 12 months
postoperatively, Dickinson et al. [26] performed a CT at
6 months postoperatively and Herford et al. [27] performed
a CT at 4 months postoperatively. Dickinson et al. [26]
Table 1 The search results and result of title and abstract screening
Search Unique
results
Met inclusion
criteria
Excluded For full text
analysis
BMP-2 34 6 1 5
BMP-7 10 0 0 0
TGF-β 71 0 0 0
PDGF 22 0 0 0
IGF 31 0 0 0
FGF 86 0 0 0
VEGF 19 0 0 0
PRP 18 7 6 1
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Orthopantomogram and on periapical films.
Length of follow-up differed between the three studies.
Herford et al. [27] reviewed the patients after 4 months,
whereas Alonso et al. [25] and Dickinson et al. [26]
reviewed the patients after 1 year. Alonso et al. [25] and
Dickinson et al. [26] assessed the morbidity of the surgical
procedures during the first year, whereas Herford et al. [27]
did not mention postoperative morbidity, nor complications.
The studies by Alonso et al. [25] and Dickinson et al.
[26] are randomised controlled trials, whilst the study by
Herfordetal.[27] is a controlled retrospective review; hence,
the level of evidence is lower for Herford et al. [27]. Table 3
shows a summary of the study design of the three articles.
Results
Success of the reconstruction of the alveolar cleft is
determined by the amount of bone formation in the cleft,
bone height of the alveolar ridge and the position of the
bone in the cleft. Bone in the supra-apical area supports the
alar base. Bone in the alveolar area provides continuity to
the alveolar ridge and gives support to the teeth adjacent to
and in the cleft. Secondly, bone quality and functionality
are of importance. Parameters for bone quality and
functionality are successful eruption of teeth in the
reconstructed cleft, periodontal status of teeth adjacent to
and in the reconstructed cleft, successful orthodontic
movement of teeth into the reconstructed cleft and
successful osseointegration of dental implants in the
reconstructed cleft. Complications and adverse events
should also be taken into account.
Bone quantity
Dickinson et al. [26] reported more bone formation in the
cleft in the rhBMP-2 group (95%) compared to the control
group (63%). Alonso et al. [25] and Herford et al. [27]
reported slightly less bone formation in the cleft in the
rhBMP-2 group compared to the control group, although
the differences (5.8% and 7%) seem not significant. Alonso
et al. [25] further measured more bone after 12 months
compared to after 6 months. In the study by Herford et al.
[27], two patients in the rhBMP-2 group showed signifi-
cantly less bone formation in the cleft than the other
patients; the authors explain this by possible wound
breakdown of the nasal mucosal layer.
Bone height was measured by Alonso et al. [25] and by
Dickinson et al. [26]. Alonso et al. [25] reported lower bone
height in the rhBMP-2 group (10.2 mm) than in the control
group (13.9 mm), whereas Dickinson et al. [26] reported
Table 2 The selected articles
Authors Title Published in Year
Alonso et al. [25] Evaluation of maxillary alveolar reconstruction using a resorbable collagen
sponge with recombinant human bone morphogenetic protein 2 in cleft lip
and palate patients
Tissue Eng Part C Methods 2010
Dickinson et al. [26] Reduced morbidity and improved healing with bone morphogenic protein-2
in older patients with alveolar cleft defects
Plast Reconstr Surg 2008
Herford et al. [27] Bone morphogenetic protein-induced repair of the premaxillary cleft J Oral Maxillofac Surg 2007
Table 3 Analysis of selected articles
Alonso et al. [25] Dickinson et al. [26] Herford et al. [27]
Total number of patients 16 21 12
rhBMP-2 group 8 9 10
Type of alveolar cleft Unilateral only Unilateral only Unilateral only
Timing of intervention Mixed dentition Skeletally mature Mixed dentition
Carrier used for rhBMP-2 Absorbable collagen sponge Absorbable collagen sponge Absorbable collagen sponge
Control group graft Particulate iliac crest
cancellous bone
Particulate iliac crest
cancellous bone
Particulate iliac crest
cancellous bone
Method for measuring
outcome
CT, coronal CT slices CT
a, 3D CT reconstructions
a,
OPG, periapical films
CT
Follow-up 12 months 12 months 4 months
Type of study Randomised controlled trial Randomised controlled trial Retrospective controlled review
aAlthough follow-up was 12 months, CT scans were performed at 6 months postoperatively by Dickinson et al. [26]
300 Clin Oral Invest (2011) 15:297–303higher bone height in the rhBMP-2 group (85%) than in the
control group (70%).
The position of the bone in the cleft was described by
Alonso et al. [25]; in the rhBMP-2 group, most bone was
deposited in the supra-apical area of the cleft, whereas in
the control group, most bone was seen in the alveolar area.
The reported bone formation and bone height in the cleft
are displayed in Table 4.
Bone quality
Alonso et al. [25] reported that tooth eruption occurred
without complications in both the rhBMP-2 group and the
control group. Dickinson et al. [26] inserted dental implants
in 2 out of 9 patients in the rhBMP-2 group and in 1 out of
12 patients in the control group. These implants all showed
successful osseointegration. Other information on bone
quality, i.e. orthodontic movement of teeth into the cleft
area or periodontal status, was not provided.
Complications and adverse events
Alonso et al. [25] observed local postoperative swelling in
37.5% of the patients in the rhBMP-2 group and significant
donor site pain in 87.5% of the patients in the control
group. Dickinson et al. [26] reported that the control group
showed significant donor site pain, more wound healing
problems, longer hospital stay and greater overall cost of
the procedure (Table 5).
Discussion
The main advantage of growth factor-aided tissue engi-
neering is the avoidance of a second surgical site needed for
the harvest of autologous bone. This results in shortening of
the operation time, absence of donor site morbidity, shorter
hospital stay and reduction of overall cost.
Promising results with growthfactor-aided tissueengineer-
ing techniques have been obtained in several fields. However,
for the reconstruction of the alveolar cleft in CLAP, only three
studies were found that assessed growth factor-aided bone
tissue engineering techniques and met our selection criteria.
We found no studies on BMP-7, TGF-β, PDGF, IGF, FGF,
VEGForPRP thatmet our selectioncriteria.The three studies
that met our selection criteria all assessed BMP-2-aided bone
tissue engineering. These three studies used the same bone
tissue engineering kit (Infuse® Bone Graft) for the recon-
struction of clefts in the experimental group and autologous
cancellous bone of the iliac crest in the control group. It is
remarkable that only studies with BMP-2 were published and
that these studies all used the same product produced by the
same company. The similarities with regard to study design
and the growth factor used make comparison of the studies
feasible. On the other hand, the patient numbers in the three
studiesaresmall,andtherewassomevariationinthetimingof
the procedure: in two studies, the alveolar clefts were
reconstructed during the stage of mixed dentition [25, 27],
whereas in the other study, clefts were reconstructed in
skeletally mature patients [26]. The volume of the alveolar
Table 4 Bone quantity results
Alonso et al. [25]
a Dickinson et al. [26] Herford et al. [27]
Bone volume rhBMP2 group 74.4% 95% 71.1%
Control group 80.2% 63% 78.1%
Bone height rhBMP2 group 10.2 mm (non-cleft side, 15.7 mm) 85% (vs. roots of adjacent teeth)
b
Control group 13.9 mm (non-cleft side, 16.1 mm) 70% (vs. roots of adjacent teeth)
b
aResults given for Alonso et al. [25] are those of the CT scans performed at 12 months postoperatively
bDickinson et al. [26] presented bone height on a scale from 0–4, 0 representing 0%; one, 25%; two, 50%; three, 75% and four, 100% bone height; the
average score on this scale in the article was converted to a percentage for this table
Alonso et al. [25] Dickinson et al. [26] Herford et al. [27]
rhBMP-2 group 37.5% local postoperative
swelling
1 patient, prolonged healing Postoperative swelling
2 patients with less than
25% bone formation
Control group 87.5% donor site pain 5 patients, partial loss of graft
1 patient, near complete
loss of graft
3 patients, persistent oronasal
fistula at 6 weeks
postoperative donor site pain
Table 5 Complications and
adverse events
Clin Oral Invest (2011) 15:297–303 301cleft prior to surgery also varied between the three studies,
namely Herford et al. [27] reported a much greater volume of
the preoperative cleft. This may be explained by the use of
preoperative orthodontic expansion of the maxillary seg-
ments by Alonso et al. [25]a n dD i c k i n s o ne ta l .[ 26]. As to
the difference in volume of the cleft between Alonso et al.
[25] and Dickinson et al. [26], the different timing of the
procedure should again be taken into account. Nevertheless,
the results clearly indicate that rhBMP-2 delivered in an
absorbable collagen sponge carrier can create a bony bridge
in alveolar cleft patients with sufficient volumes of bone,
comparable with the amount achieved in iliac crest cancel-
lous bone grafting. An interesting finding by Alonso et al.
[25] was the progressive formation of alveolar bone: there
appeared to be more bone after 12 months compared to after
6 months in the BMP-2 group. This finding may indicate
that evaluation after 4 months, as in the study by Herford et
al. [27], is perhaps too quick to assess the final result of the
treatment. If this is true, evaluation at a later stage may show
more favourable results.
A specifically interesting subset of patients are skeletally
mature patients as these patients showed better results in the
BMP-2 group in terms of bone quantity, less complications
and less adverse events compared to patients who received
cancellous bone of the iliac crest [26]. Inferior outcome in
patients treated with bone grafting after the stage of mixed
dentition, i.e. after the eruption of the permanent canines, has
been reported previously [28–30]. Perhaps, this subset of
patients can benefit even more from the application of BMP-2.
It is thought that osteogenesis is a complex process that
requires certain combinations of growth factors on specific
moments during bone formation. Therefore, it was surpris-
ing that the use of just one growth factor in combination
with an osteoconductive scaffold led to bone formation. A
possible explanation is that BMP-2 stands at or near the top
of a cascade of growth factors needed for bone formation
and that through biological feedback mechanisms, the right
combination of growth factors is attained.
The alveolar bone is a unique bone structure. Besides
providing mechanical strength to skeletal system and
support for the surrounding soft tissues, the alveolar bone
also gives support to teeth and allows tooth eruption,
orthodontic movement of teeth into the reconstructed cleft,
and, if indicated, osseointegration of dental implants.
Unfortunately, quality of bone formation in this respect
was not assessed in any of the three studies. Future studies
are required to address these issues.
Conclusion
The three studies that met our selection criteria all assessed
BMP-2-aided bone tissue engineering. We found no studies
on BMP-7, TGF-β, PDGF, IGF, FGF, VEGF or PRP that
met our selection criteria.
The application of BMP-2 on an absorbable sponge
consisting of type 1 bovine collagen for the reconstruction
of the alveolar cleft in CLAP is a very promising technique.
Favourable results with BMP-2 have been obtained in terms
of quantity of bone formation. The application of BMP-2
results in shortening of the operation time, absence of donor
site morbidity, shorter hospital stay and reduction of overall
cost.
Recommendation
Larger and well-designed randomised controlled trials are
needed to compare the results from BMP-2-aided bone
tissue engineering with the results of autologous bone grafts
in alveolar bone grafting. In these trials, bone formation
should be assessed during at least 12 months. For the
assessment of quantity of bone formation, height of bone
and location of bone in the cleft defect should be specified.
For the assessment of quality of bone, tooth eruption should
be evaluated as well as periodontal status of teeth adjacent
to and in the former cleft area, success of orthodontic
movement of teeth into the former cleft area and osseointe-
gration of dental implants.
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